Risk measures and the cost of equity in the new economy biotechnology industry
by Perry Sadorsky, Irene Henriques
Global Business and Economics Review (GBER), Vol. 5, No. 1, 2003

Abstract: The cost of equity is important in valuing new investment opportunities and in evaluating the ongoing performance of existing business projects. This is especially true in the new economy biotechnology industry. The purpose of this paper is to calculate the cost of equity for the Canadian biotechnology industry using several different risk measures. The risk measures include systematic risk, total risk, downside risk, and value at risk. The results are useful for managers, budget planners, investors, policy makers, and others who are interested in the financing and risk management of new economy firms.

Online publication date: Mon, 07-Feb-2005

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the Global Business and Economics Review (GBER):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com